SLOW-RELEASE morphine product Kapanol from Mayne Pharma has been given the Therapeutic Goods Administration nod for a new indication: treatment of chronic breathlessness in patients with advanced disease.
The Kapanol approval applies to low dose forms, 10mg and 20mg, and could improve the lives of more than 70,000 Australians, Mayne Pharma CEO Scott Richards said.
An application for this indication has been made to the PBAC for funding via the PBS.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 19
